《大行报告》高盛首予翰森制药(03692.HK)「买入」评级目标价27.5元
高盛报告指翰森制药(03692.HK)是一家领先的特种药品制造商,并正在转型为「仿制药+创新」业务模式,与恒瑞及中生制药(01177.HK)相似。该行指,翰森制药的优势在於公司在中枢神经系统和肿瘤学有市场领导地位;是新药及首次上市仿制药的上市渠道;已建立商业化专业知识;以及有强劲资金支持研发及潜在并购。
该行首予翰森制药「买入」评级,目标价27.5元,2018-2021年销售年复合增长率料为26%,盈利复合年增长率料为30%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.